drugset
drugset / Trial / NCT06062641

Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL

NCT06062641 ↗

Phase 2 Not yet recruiting 50 enrolled Ruijin Hospital
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of selinexor combined with R-GDP regimen in the treatment of patients with TP53-altered relapsed or refractory B-cell lymphoma.

Timeline

Start
2023-10-30
Primary completion
2024-04-30
Completion
2027-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Selinexor Other / unclassified 40 mg Oral
Background Cisplatin Other / unclassified 25 mg/m2 Intravenous
Background Dexamethasone Small molecule 20 mg Oral
Background Dexamethasone Small molecule 40 mg Oral
Background Gemcitabine Small molecule 1 g/kg Intravenous
Background Rituximab Monoclonal antibody 375 mg/m2 Intravenous

Indications

B-cell non-Hodgkin lymphoma